Thelansis

  Erosive esophagitis (EE) is a common gastroesophageal reflux disease (GERD) symptom. Without continued treatment, most patients with healed EE (approximately 80% – 90%) will relapse within 6 – 12 months. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and mortality rates. Although there is some overlap in acid exposure among esophagitis grades, the severity of EE is related to the duration of esophageal acid exposure. Because of their ability to control esophageal acid exposure, symptoms,   and esophagitis, acid-suppressive therapy with proton pump inhibitors   (PPIs) is recommended as first-line therapy for GERD and EE. Esomeprazole is the S-enantiomer of the racemic PPI omeprazole, with which it shares the exact pharmacodynamic mechanism of action. Both of these PPIs block the proton pump H+/K+ adenosine triphosphatase.   Thelans...